Cover Image
市場調查報告書

全球非何杰金氏淋巴瘤治療藥市場:成長,趨勢及預測(2017年∼2022年)

Global Non-Hodgkin Lymphoma Therapeutics Market - Growth, Trends and Forecasts (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 603202
出版日期 內容資訊 英文 211 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球非何杰金氏淋巴瘤治療藥市場:成長,趨勢及預測(2017年∼2022年) Global Non-Hodgkin Lymphoma Therapeutics Market - Growth, Trends and Forecasts (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 211 Pages
簡介

國立癌症研究所報告,2016年非何杰金氏淋巴瘤的新罹患數為7萬2580件,在非何杰金氏淋巴瘤起因的死亡案例是2萬150件。市場有強力的開發平台,不過,由於Rituximab的化療主導目前的市場,後期階段所使用的NHL治療藥暢銷流行。預計非何杰金氏淋巴瘤的治療所使用的Rituximab的銷售量拉抬這個市場成長。

本報告提供全球非何杰金氏淋巴瘤治療市場相關調查,市場概要,各治療類型、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會、課題分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 市場定義
  • 粒度分級單位
  • 基本貨幣
  • 期間的重新評估與預測
  • 一般調查的前提條件
  • 報告的說明

第2章 調查方法

  • 簡介
  • 分析方法論
  • 調查的時間軸
  • 調查的階段
    • 2次調查
    • 討論指南
    • 市場工程&計量經濟學模式

第3章 摘要整理

第4章 主要推論

第5章 市場概要及產業趨勢

  • 目前市場方案
  • 市場概況
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 市場成長要素
    • 難治性/復發性疾病治療的未滿足需求
    • 有前途的開發平台
  • 市場阻礙因素
    • Rituximab反抗性非何杰金氏淋巴瘤的增加
    • 嚴格的法規指南
  • 市場機會
  • 主要課題

第7章 全球非何杰金氏淋巴瘤治療藥:市場區隔

  • 治療各類型
    • 化療
    • 免疫療法
    • 標靶治療
    • 放射線治療
    • 幹細胞移植

第8章 全球非何杰金氏淋巴瘤治療藥市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙、葡萄牙
    • 斯堪地那維亞各國
    • 荷比盧三國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲、紐西蘭
    • 韓國
    • 其他
  • 中東、非洲
    • 波灣合作理事會(GCC)
    • 南非
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他

第9章 競爭情形

  • M&A
  • 新產品的銷售
  • 協定,合作,夥伴關係

第10章 企業簡介

  • Roche
  • Seattle Genetics
  • Spectrum Pharmaceuticals
  • Celgene
  • Millennium/Johnson-Johnson
  • Merck
  • Pharmacyclics/Janssen Biotech
  • Kyowa Hakko Kirin
  • CTI BioPharma
  • 其他

第11章 分析師對投資機會的見解

第12章 市場未來展望

目錄

The global non-Hodgkin's lymphoma treatment market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach USD XX million by 2021.

The National Cancer Institute reports an estimated 72580 new cases and 20150 deaths in 2016, due to non-Hodgkin's lymphoma. Although the market has a strong pipeline, no late-stage drugs in the NHL pipeline are expected to achieve blockbuster status, as rituximab-based chemotherapy dominates the NHL treatment market. Roche's Gazyva is being evaluated across the follicular lymphoma and diffuse large B-cell lymphoma settings, while the developers of Arzerra, copanlisib, and duvelisib are focusing on indolent NHL. Rituximab sales are expected to boost the current market during the forecast period.

Global Non-Hodgkin's Lymphoma Treatment - Market Dynamics

The report details several factors driving and restraining the market, some of which are discussed below.

Drivers

Unmet need for treatment of refractory/relapsed disease

Promising pipeline

Restraints

Increasing rituximab resistance

Stringent regulatory guidelines

Market Segmentation

The global non-Hodgkin's Lymphoma treatment market has been segmented by type of treatment into chemotherapy (Abitrexate, Adcetris, Ambochlorin. Arranon, Belinostat, Carmustine. Cyclophosphamide and others), immunotherapy, targeted therapy, radiation and stem cell transplant. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.

Some of the key players in the market are:

Roche

Seattle Genetics

Spectrum Pharmaceuticals

Celgene

Millennium/Johnson-Johnson

Merck

Pharmacyclics/Janssen Biotech

Kyowa Hakko Kirin

CTI BioPharma

Others

What the Report Offers

Market definition, along with identification of key drivers and restraints for the market.

Market analysis with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.

An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.

Table of Contents

1. INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Market Definition
  • 1.3 Sizing Units
  • 1.4 Base Currency
  • 1.5 Review and Forecast Period Years
  • 1.6 General Study Assumptions
  • 1.7 Report Description

2. RESEARCH METHODOLOGY

  • 2.1 Introduction
  • 2.2 Analysis Methodology
  • 2.3 Study Timeline
  • 2.4 Study Phases
    • 2.4.1 Secondary Research
    • 2.4.2 Discussion Guide
    • 2.4.3 Market Engineering & Econometric Model
    • 2.4.4 Expert Validation

3. EXECUTIVE SUMMARY

4. KEY INFERENCES

5. MARKET OVERVIEW AND INDUSTRY TRENDS

  • 5.1 Current Market Scenario
  • 5.2 Market Overview
  • 5.3 Porters Five Force Analysis
    • 5.3.1 Bargaining Power Of Suppliers
    • 5.3.2 Bargaining Power Of Buyers
    • 5.3.3 Degree Of Competition
    • 5.3.4 Threat Of Substitution
    • 5.3.5 Threat Of New Entrants

6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Unmet Need in Treatment of Refractory/Relapsed Disease
    • 6.1.2 Promising Pipeline
  • 6.2 Market Restraints
    • 6.2.1 Increasing Rituximab Resistance
    • 6.2.2 Stringent Regulatory Guidelines
  • 6.3 Market Opportunities
  • 6.4 Key Challenges

7. Global Non-Hodgkin's Lymphoma Treatment Market - Segmentation

  • 7.1 BY TYPE OF TREATMENT
    • 7.1.1 Chemotherapy
      • 7.1.1.1 Abitrexate
      • 7.1.1.2 Adcetris
      • 7.1.1.3 Ambochlorin
      • 7.1.1.4 Arranon
      • 7.1.1.5 Belinostat
      • 7.1.1.6 Carmustine
      • 7.1.1.7 Cyclophosphamide
      • 7.1.1.8 Others
    • 7.1.2 Immunotherapy
    • 7.1.3 Targeted Therapy
    • 7.1.4 Radiation
    • 7.1.5 Stem Cell Transplant

8. Global Non-Hodgkin's Lymphoma Treatment Market - Regional Shares and Forecast

  • 8.1 North America
    • 8.1.1 United States
    • 8.1.2 Canada
    • 8.1.3 Mexico
  • 8.2 Europe
    • 8.2.1 Germany
    • 8.2.2 UK
    • 8.2.3 France
    • 8.2.4 Italy
    • 8.2.5 Spain & Portugal
    • 8.2.6 Scandinavia
    • 8.2.7 Benelux
    • 8.2.8 Rest of Europe
  • 8.3 Asia-Pacific
    • 8.3.1 China
    • 8.3.2 Japan
    • 8.3.3 India
    • 8.3.4 Australia & New Zealand
    • 8.3.5 South Korea
    • 8.3.6 Rest of Asia-Pacific
  • 8.4 The Middle East and Africa
    • 8.4.1 GCC
    • 8.4.2 South Africa
    • 8.4.3 Rest of the Middle East and Africa
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of Latin America

9. Competitive Landscape

  • 9.1 Merger and Acquisition Analysis
  • 9.2 New Product Launches
  • 9.3 Agreements, Collaborations & Partnerships

10. Company Profiles

  • 10.1 Roche
  • 10.2 Seattle Genetics
  • 10.3 Spectrum Pharmaceuticals
  • 10.4 Celgene
  • 10.5 Millennium/Johnson-Johnson
  • 10.6 Merck
  • 10.7 Pharmacyclics/Janssen Biotech
  • 10.8 Kyowa Hakko Kirin
  • 10.9 CTI BioPharma
  • 10.10 Others

11. Analyst Outlook for Investment Opportunities

12. Future Outlook of the Market

Back to Top